このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma

2026年6月13日 更新者:Deling Li、Beijing Tiantan Hospital

An Investigator-Initiated Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of [177Lu]Lu-DOTA-EB-RGD2 in Patients With Recurrent High-grade Glioma

This is an investigator-initiated, Phase I clinical trial. It aims to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of a novel radiopharmaceutical, [177Lu]Lu-DOTA-EB-RGD2, in patients with recurrent high-grade gliomas. Participants will receive the drug either via intravenous infusion or directly into the tumor cavity through a pre-implanted Ommaya reservoir (a subcutaneously placed device that allows direct access to the tumor cavity). The study employs a "3+3" dose-escalation design to determine the maximum tolerated dose (MTD). Adverse events, biodistribution, and tumor response (by MRI) will be assessed. Approximately 24 patients will be enrolled across two major Chinese medical centers: Beijing Tiantan Hospital and Peking Union Medical College Hospital.

調査の概要

詳細な説明

This is a multicenter, open-label, Phase I dose-escalation study with two parallel routes of administration: intravenous (IV) and locoregional (via Ommaya reservoir into the tumor cavity). The primary objective is to determine the maximum tolerated dose (MTD) of [177Lu]Lu-DOTA-EB-RGD2 for each route using a standard "3+3" design. Three dose levels per cycle are planned for each route (IV and locoregional). Treatment is given every 3 weeks for up to 2 cycles, with possible additional cycles based on clinical benefit as judged by the investigator.

Primary endpoint: Dose-limiting toxicity (DLT) incidence during the first 6 weeks (2 cycles), graded by CTCAE v5.0.

Secondary endpoints: Adverse events (type, frequency, severity); time-activity curves and absorbed radiation doses in organs and tumors (based on whole-body planar imaging and SPECT/CT at multiple time points); pharmacokinetic parameters (AUC, Cmax, Tmax, clearance [CL], volume of distribution [Vz], terminal half-life) from blood and urine sampling; objective response rate (ORR) per RANO 2.0 (by contrast-enhanced MRI); overall survival.

Exploratory endpoints: Change in tumor αvβ3 integrin expression by NOTA-PRGD2 PET/CT; correlation between baseline NOTA-PRGD2 PET uptake and treatment response.

Sample size: Approximately 24 patients (up to 3+3 per dose level per route) using the 3+3 rule. No formal hypothesis testing is planned; descriptive statistics will be used.

Study duration: 36 months (recruitment approximately 12 months, treatment and follow-up approximately 24 months). The trial is conducted at Beijing Tiantan Hospital and Peking Union Medical College Hospital, China.

研究の種類

介入

入学 (推定)

24

段階

  • 初期フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100070
        • 募集
        • Beijing Tiantan Hospital, Capital Medical University
        • 主任研究者:
          • Deling Li, M.D.
        • コンタクト:
      • Beijing、Beijing Municipality、中国、100730
        • 募集
        • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
        • コンタクト:
        • 主任研究者:
          • Zhaohui Zhu, M.D.

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  1. The participant must sign the informed consent form before participation.
  2. Age ≥ 18 years.
  3. Histologically confirmed glioblastoma (WHO classification) after surgical resection or biopsy.
  4. Participants receiving corticosteroids (e.g., dexamethasone) must be on a stable or decreasing dose ≤ 4 mg/day (or equivalent) for at least 7 days before start of study treatment.
  5. Adequate bone marrow and organ function confirmed by laboratory tests performed ≤ 14 days before first study treatment:

    Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Hemoglobin ≥ 10.0 g/dL; Serum creatinine ≤ 1.5 × upper limit of normal (ULN); Total bilirubin ≤ 1.5 × ULN; albumin ≥ 30 g/L; ALT and AST < 3 × ULN in absence of liver metastases, or < 5 × ULN if liver metastases present; Coagulation: activated partial thromboplastin time (APTT) ≤ 2 × ULN, international normalized ratio (INR) ≤ 1.5 (if not receiving anticoagulation therapy);

  6. Evidence of disease progression (PD) by RANO 2.0 criteria confirming recurrence: ≥ 25% increase in product of perpendicular diameters or > 40% increase in tumor volume compared to baseline after initial treatment or best response, while on stable or increasing corticosteroid dose. Clinical deterioration or increased corticosteroid dose alone is insufficient. MRI contrast enhancement, MRS, and/or metabolic PET should help differentiate true progression from radiation necrosis/pseudoprogression. Also, at least one bi-dimensionally measurable contrast-enhancing lesion with shortest diameter ≥ 10 mm must be present on MRI.
  7. For participants receiving Ommaya reservoir implantation for locoregional administration, surgery must be completed at least 2 weeks before first radionuclide therapy, with no postoperative complications. Baseline MRI for efficacy assessment must be performed at least 2 weeks after implantation and before first radionuclide therapy.
  8. Tumor uptake confirmed by NOTA-PRGD2 PET/CT after diagnosis of recurrence and before radionuclide therapy. For participants with Ommaya reservoir, PET/CT must be performed at least 2 weeks after implantation and before first radionuclide therapy.
  9. Life expectancy > 6 months.
  10. Karnofsky Performance Status (KPS) score ≥ 50.

Exclusion Criteria:

  1. Receiving any other concurrent treatment for glioblastoma outside this study.
  2. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed from the start of [177Lu]Lu-DOTA-EB-RGD2 treatment until 6 months after treatment.
  3. Refusal to use effective contraception during sexual intercourse from informed consent until 6 months after the last dose of study drug.
  4. Inability to tolerate imaging procedures, repeated blood sampling, or poor venous access.
  5. Cardiac dysfunction, clinically significant cardiac disease history, or ECG abnormalities indicating a major safety risk, including:

(1) Documented myocardial infarction, angina pectoris, cardiomyopathy, symptomatic pericarditis, or coronary artery bypass grafting within 6 months before enrollment.

(2) Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following: (a) risk factors for torsade de pointes (TdP) including uncorrected hypocalcemia, hypokalemia, hypomagnesemia, history of heart failure, or clinically significant/symptomatic bradycardia; (b) use of medications known to prolong the QT interval and/or cause TdP that cannot be discontinued or replaced with a safer alternative (e.g., within 5 half-lives or 7 days before study drug); (c) inability to determine the Fridericia-corrected QT interval (QTcF).

(3) Clinically significant arrhythmia (e.g., ventricular tachycardia), complete left bundle branch block, high-grade atrioventricular block (e.g., bifascicular block, Mobitz type II, third-degree AV block).

(4) Resting QTcF ≥ 450 ms (male) or ≥ 460 ms (female). (5) Left ventricular ejection fraction (LVEF) < 50% by echocardiography. (6) Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg, regardless of antihypertensive use.

6. Other malignancy within 5 years before study drug administration, except adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer after curative surgery, carcinoma in situ after curative surgery, or papillary thyroid cancer after curative surgery (hormonal therapy for non-metastatic prostate or breast cancer allowed).

7. Abnormal serum virology (HBsAg, T. pallidum antibody, HIV antibody, HCV antibody). Patients with untreated active hepatitis B who are willing to receive anti-HBV therapy during study treatment are allowed; patients with inactive hepatitis B are allowed; patients with inactive hepatitis C (HCV antibody positive but HCV RNA below lower limit of detection) are allowed.

8. Use of bevacizumab for glioblastoma or supportive care (e.g., edema reduction) within 60 days before start of study treatment.

9. Patients with disease progression within the first 12 weeks after completion of radiotherapy are excluded from recurrent disease trials.

10. Prior intracranial locoregional drug therapy before [177Lu]Lu-DOTA-EB-RGD2 treatment.

11. Active intracranial or intratumoral hemorrhage detected by CT/MRI. 12. Seizure within 14 days before start of study treatment; epilepsy or increased intracranial pressure uncontrolled by medication.

13. Grade 4 myelosuppression from prior anticancer therapy that has not recovered within 2 weeks, or grade 3 myelosuppression requiring >6 weeks to recover.

14. Blood transfusion within 4 weeks before screening to meet eligibility criteria.

15. Known hypersensitivity or delayed allergic reaction to any component of [177Lu]Lu-DOTA-EB-RGD2 or similar drugs.

16. Severe disease of the cardiac, respiratory, central nervous system, renal, hepatic, or other organ systems that, in the investigator's opinion, may increase participant safety risk.

17. Active infection requiring intravenous antibiotics (bacterial, fungal, or viral) within 4 weeks before first dose, or any other uncontrolled active infection deemed clinically significant by the investigator.

18. History of drug or alcohol abuse within one year before screening, long-term drug use, or psychiatric illness that may affect compliance.

19. Participation in another investigational drug or device trial within 4 weeks before first dose.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Intravenous Administration of [177Lu]Lu-DOTA-EB-RGD2
Participants receive [177Lu]Lu-DOTA-EB-RGD2 via intravenous infusion 20-30 minutes once every 3 weeks (Q3W) for up to 2 cycles (6 weeks). Dose escalation follows a 3+3 design with three dose levels per cycle. Additional cycles may be given based on clinical benefit.
A long-circulating radiolabeled peptide targeting integrin αvβ3. The radiopharmaceutical consists of an RGD2 peptide conjugated to a DOTA chelator and an albumin-binding (EB) motif, labeled with Lutetium-177 (half-life 6.7 days). It is administered intravenously (20-30 min infusion) or locoregionally via Ommaya reservoir directly into the tumor cavity. The study evaluates safety, tolerability, dosimetry, and preliminary efficacy in recurrent high-grade glioma.
実験的:Locoregional Administration of [177Lu]Lu-DOTA-EB-RGD2
Participants receive [177Lu]Lu-DOTA-EB-RGD2 directly into the tumor cavity through a previously implanted Ommaya reservoir once every 3 weeks (Q3W) for up to 2 cycles (6 weeks). Dose escalation follows a 3+3 design with three dose levels per cycle. Additional cycles may be given based on clinical benefit.
A long-circulating radiolabeled peptide targeting integrin αvβ3. The radiopharmaceutical consists of an RGD2 peptide conjugated to a DOTA chelator and an albumin-binding (EB) motif, labeled with Lutetium-177 (half-life 6.7 days). It is administered intravenously (20-30 min infusion) or locoregionally via Ommaya reservoir directly into the tumor cavity. The study evaluates safety, tolerability, dosimetry, and preliminary efficacy in recurrent high-grade glioma.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of Dose-Limiting Toxicities (DLTs)
時間枠:Within 6 weeks (42 days) after the first dose (during the first two cycles; each cycle is 21 days)

DLTs are defined as protocol-specified adverse events occurring during the first 6 weeks (2 cycles) after the first dose, graded by NCI CTCAE v5.0. DLTs include:

Grade ≥3 neurological toxicities (e.g., grade 3 CNS necrosis, grade 3 decreased consciousness, grade 3 hydrocephalus, grade 3 seizure, grade 3 headache that lasts over 24 hours with treatments, grade ≥4 cerebral edema); Grade ≥3 hematologic toxicities (e.g., grade 3 febrile neutropenia, grade 3 anemia lasting >7 days, grade 3 lymphopenia with infection, grade 4 neutropenia lasting >7 days, grade 4 thrombocytopenia or grade 3 with bleeding); Any grade ≥3 non-hematologic toxicity (except transient grade 3 nausea/vomiting/diarrhea lasting <3 days, grade 3 fatigue lasting <1 week, or electrolyte abnormality lasting less than 72 hours and resolved by supportive care); Any Hy's law event (e.g., ALT or AST > 3-fold upper limit normal); Death or significant clinical intervention related to the study drug.

Within 6 weeks (42 days) after the first dose (during the first two cycles; each cycle is 21 days)

二次結果の測定

結果測定
メジャーの説明
時間枠
Incidence and severity of adverse events (AEs)
時間枠:From the first dose (Day 1) until study completion (up to 17 months)
All adverse events (AEs), serious AEs (SAEs), treatment-emergent AEs (TEAEs), and deaths, graded by NCI CTCAE v5.0. Assessment includes changes in vital signs, physical examination, electrocardiogram (ECG), echocardiogram (for participants >60 years), laboratory tests (hematology, serum chemistry, coagulation, urinalysis), and serum pregnancy test (for females of childbearing potential). AE resolution or progression is tracked throughout follow-up.
From the first dose (Day 1) until study completion (up to 17 months)
Radiation Dosimetry
時間枠:From the first dose up to 192 hours (Day 8)
Time-activity curves (TACs) derived from whole-body planar imaging and SPECT/CT at multiple time points post-injection. Absorbed doses to the tumor and major organs are calculated using the MIRD methodology.
From the first dose up to 192 hours (Day 8)
Maximum Tolerated Dose (MTD)
時間枠:Within 6 weeks (42 days) after the first dose
The highest dose level at which ≤1 of 6 participants experiences a DLT during the first 6 weeks (2 cycles), determined separately for the intravenous and locoregional administration arms using the 3+3 dose-escalation design.
Within 6 weeks (42 days) after the first dose
Area Under the Concentration-Time Curve (AUC) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
時間枠:Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
AUC calculated from time zero to last measurable time point and/or to infinity, measured from venous blood samples.
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
Objective Response Rate (ORR)
時間枠:Baseline, Day 22 (±3 days), Day 42 (±7 days), then every 6 weeks until progression, death, or start of new therapy (up to 17 months)
Proportion of participants achieving complete response (CR) or partial response (PR) on contrast-enhanced MRI according to RANO 2.0 criteria. CR is defined as disappearance of all enhancing and non-enhancing lesions without new lesions; PR is defined as a ≥50% decrease in the product of perpendicular diameters from baseline.
Baseline, Day 22 (±3 days), Day 42 (±7 days), then every 6 weeks until progression, death, or start of new therapy (up to 17 months)
Overall Survival (OS)
時間枠:From the first dose up to 17 months (study duration)
Time from the first dose of [177Lu]Lu-DOTA-EB-RGD2 to death from any cause. Participants alive at study end or lost to follow-up are censored at their last known alive date.
From the first dose up to 17 months (study duration)
Maximum Plasma Concentration (Cmax) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
時間枠:Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
Cmax directly observed from concentration-time data, measured from venous blood samples.
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
Time to Maximum Plasma Concentration (Tmax) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
時間枠:Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
Tmax corresponding to Cmax, measured from venous blood samples.
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
Systemic Clearance (CL) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
時間枠:Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
CL calculated as Dose/AUC, measured from venous blood samples.
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
Volume of Distribution During Terminal Phase (Vz) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
時間枠:Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
Vz calculated as CL/λz, measured from venous blood samples.
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
Terminal Half-Life (t1/2) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
時間枠:Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
t1/2 calculated from the terminal phase of the concentration-time curve, measured from venous blood samples.
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)

その他の成果指標

結果測定
メジャーの説明
時間枠
Change in Tumor Uptake of NOTA-PRGD2 on PET/CT
時間枠:Baseline (within 42 days before the first dose) and Day 42 (±7 days) after the first dose
Changes in tumor SUVmax, SUVmean, and tumor-to-background ratio (TBR) from baseline to post-treatment PET/CT scans, as an exploratory biomarker of target engagement.
Baseline (within 42 days before the first dose) and Day 42 (±7 days) after the first dose

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Deling Li, M.D.、Beijing Tiantan Hospital
  • 主任研究者:Zhaohui Zhu、Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年6月1日

一次修了 (推定)

2026年12月31日

研究の完了 (推定)

2027年1月31日

試験登録日

最初に提出

2026年6月10日

QC基準を満たした最初の提出物

2026年6月13日

最初の投稿 (実際)

2026年6月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月18日

QC基準を満たした最後の更新が送信されました

2026年6月13日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

The decision on whether to share individual participant data (IPD) has not yet been finalized. This is a Phase I investigator-initiated trial with a small sample size (approximately 24 participants). Data sharing will be considered in accordance with institutional policies, patient consent, and Chinese regulatory requirements. Any future sharing would require additional ethical approval and a data transfer agreement.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する